CDM-3008 showed anti-SARS-CoV-2 activity in HeLa cells with an IC50 of 0.78 μM
Int J Mol Sci. 2021 Oct 28;22(21):11641
NCI-H1395 cells
2 µM
24 hours
RO8191 treatment slowed down the changes induced by Amuc_1100, inhibiting the recruitment and toxicity of CD8+ T cells.
Microb Biotechnol. 2024 Jul;17(7):e14522
A549 cells
2 µM
24 hours
RO8191 treatment slowed down the changes induced by Amuc_1100, inhibiting the recruitment and toxicity of CD8+ T cells.
Microb Biotechnol. 2024 Jul;17(7):e14522
Calu-3 cells
0.001-10 µM
3 days
CDM-3008 showed anti-SARS-CoV-2 activity in Calu-3 cells with an IC50 of 2.54 μM
Int J Mol Sci. 2021 Oct 28;22(21):11641
N2a-58 cells
0.5, 5, 50, 250, 500 µM
48 hours
RO8191 treatment did not alter PrPC levels in N2a-58 cells but dose-dependently increased OAS1a expression.
Brain. 2019 Apr 1;142(4):1035-1050
N2a-22L cells
0.5, 5, 50, 250, 500 µM
48 hours
RO8191 treatment significantly reduced PrPSc levels in N2a-22L cells in a dose-dependent manner.
Brain. 2019 Apr 1;142(4):1035-1050
REP-HepG2-NTCP cells
1 and 10 µM
9 days
Evaluated the anti-HBV effect of CDM-3008, showing significant reduction in HBV DNA levels
Cell Death Discov. 2021 Jun 2;7(1):130
RO8191 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
Myocardial infarction model
Intragastric administration
10 mg/kg
Single dose 30 min before MI surgery
To assess the effect of RO8191 on the anti-inflammatory and cardiac reparative effects of hEPs in MI treatment, showing that RO8191 attenuated these beneficial effects of hEPs.
Adv Sci (Weinh). 2023 Sep;10(27):e2300470
C57BL/6 mice
Subcutaneous allograft tumour model
Intraperitoneal injection
2 mg/kg
Not specified
RO8191 attenuated the inhibitory effect of Amuc_1100 on tumour growth and reduced the number of tumour-infiltrating CD8+ T cells.
Microb Biotechnol. 2024 Jul;17(7):e14522
ICR mice
LPS-induced acute lung injury model
In vitro
2 μM
Not used
Partially reversed the inhibitory effects of IRD on inflammation
J Inflamm Res. 2021 Feb 5;14:341-354.
DdY mice
22L prion infection model
Intraperitoneal injection
2.0 mg/kg/day
Administered every other day starting from 2 days post-inoculation until sacrifice
RO8191 treatment significantly prolonged the survival of infected mice and reduced PrPSc levels and pathological changes in the brain and spleen.
Brain. 2019 Apr 1;142(4):1035-1050
Rats
Post-LT liver fibrosis model
Oral
20 mg/kg
Daily for 10 days
To study the effect of RO8191 on liver fibrosis, results showed RO8191 increased the stage of liver fibrosis and the levels of COL1A1 and ACTA2.
搜索
